Clinical trials: Dry Mouth
Dry Mouth, Xerostomia
Clinical Evaluation of MucoPEG™ for Xerostomia
The purpose of this study is to evaluate the effectiveness of the oral rinse comparing to MucoPEG™ and Biotene®. This is a randomized open-label crossover study with 42 patients receiving treatment.
- Trial name
- CEMPEG (NCT04986501)
- Testing
- MucoPEG, Biotene
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- SunBio, Inc.
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Dry Mouth, Xerostomia
"Hyaluronan" Formulation for Type 2 Diabetic Patients With Dry Mouth
An increased incidence of dental caries in association with poorly controlled diabetes has also been reported, Xerostomia (dry mouth) has been reported to be a common complaint of patients with diabetes, Without adequate saliva…
- Conditions
- Dry Mouth, Xerostomia, Type 2 Diabetics
- Trial name
- NCT03281486
- Testing
- HA formulation Oral Spray
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- You First Services
Dry Mouth
Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control
The objective of this study is to evaluate dry mouth relief in subjects with self-reported feeling of dry mouth after using an experimental mouth rinse or a positive control compared to a water control.
- Trial name
- NCT04189081
- Testing
- dry mouth rinse, Water Control
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Dry Mouth
A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse
The objective of this pilot study is to determine if an experimental mouth rinse and a marketed dry mouth rinse are more effective in relieving dry mouth compared to water.
- Trial name
- NCT04152642
- Testing
- Marketed Dry Mouth Rinse, Water control, Experimental Dry Mouth Rinse
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Dry Mouth, Xerostomia.Hyaluronic Acid, Xylitol
CLINICAL EVALUATION OF THE EFFICACY OF AN INTRA ORAL SPRAY FOR PATIENTS WITH XEROSTOMIA
This cross-over group, double-blind, randomized, single center, study will enroll 26 subjects to target at least 24 subjects completing the study.Following an initial 3-5 minute evaluation of resting salivary flow, subjects will…
- Trial name
- NCT04719091
- Testing
- Lubricity
- Volunteers
- 26 people
- Sponsor
- You First Services
Dry Mouth, Xerostomia
"Hyaluronan" Formulation for Dry Mouth in Sleep Apnea Patients
During routine clinical practice, it is observed that patients with suspected obstructive sleep apnea (OSA) often reported waking up with a dry mouth during the night or in the morning.
- Conditions
- Dry Mouth, Xerostomia, OSA, Sleep Apnea
- Trial name
- NCT03295019
- Testing
- Test Oral Spray
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- You First Services
Dry Mouth Associated With Sjogren's Syndrome, Xerostomia
A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome
This clinical study is to determine whether daily administration of a formulation of 552-02 improves the dry mouth condition in subjects with primary Sjögren's syndrome.
- Trial name
- NCT00852839
- Testing
- 552-02
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- Parion Sciences
Dry Mouth
Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601211
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Dry Mouth
Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601874
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Dry Mouth
Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period…
- Trial name
- NCT00602524
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Dry Mouth
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence…
- Trial name
- NCT00618059
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Dry Mouth
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
- Trial name
- NCT01903109
- Testing
- Cevimeline
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Dry Mouth
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
- Trial name
- NCT01903122
- Testing
- Cevimeline
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories